v3.26.1
Revenue (Tables)
 6 Months Ended
Jul. 03, 2026
Revenue [Abstract]  
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Customer, Extent of Reliance The Company disaggregates its revenue into the following geographic/product type groups within its segments:
Three Months EndedSix Months Ended
July 3, 2026July 4, 2025July 3, 2026July 4, 2025
(In thousands)
Prevention & Recovery:
U.S. Bracing & Support$127,610 $120,850 $242,493 $235,936 
U.S. Other P&R (1)
59,637 70,823 115,499 137,445 
International P&R101,001 98,897 202,274 189,773 
Total Prevention & Recovery288,248 290,570 560,266 563,154 
Reconstructive:
U.S. Recon137,829 129,493 287,037 267,370 
International Recon156,705 144,482 324,630 292,855 
Total Reconstructive 294,534 273,975 611,667 560,225 
Total$582,782 $564,545 $1,171,933 $1,123,379 
(1) The three and six months ended July 4, 2025 include $14.4 million and $27.2 million, respectively, of sales from the October 2025 divestiture of the Company’s Dr. Comfort Footcare Solutions product line.
Financing Receivable, Allowance for Credit Loss
A summary of the activity in the Company’s allowance for credit losses included within Trade receivables in the Condensed Consolidated Balance Sheets is as follows:
Six Months Ended July 3, 2026
Balance at
Beginning
of Period		Charged to Expense, netWrite-Offs, Deductions, and Other, netForeign
Currency
Translation		Balance at
End of
Period
(In thousands)
Allowance for Credit Losses$25,609 $5,477 $(2,633)$(269)$28,184